mirtazapine has been researched along with Glaucoma, Angle Closure in 1 studies
Mirtazapine: A piperazinoazepine tetracyclic compound that enhances the release of NOREPINEPHRINE and SEROTONIN through blockage of presynaptic ALPHA-2 ADRENERGIC RECEPTORS. It also blocks both 5-HT2 and 5-HT3 serotonin receptors and is a potent HISTAMINE H1 RECEPTOR antagonist. It is used for the treatment of depression, and may also be useful for the treatment of anxiety disorders.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This case report describes a patient with major depressive disorder, who experienced AAC after the first dosage of mirtazapine treatment, and highlights the importance of close monitoring of individuals under antidepressant treatment particularly immediately after initiation of the drug." | 1.42 | Mirtazapine-induced acute angle closure. ( Durmaz, O; Durna, MM; Kahraman, N, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kahraman, N | 1 |
| Durmaz, O | 1 |
| Durna, MM | 1 |
1 other study available for mirtazapine and Glaucoma, Angle Closure
| Article | Year |
|---|---|
Mirtazapine-induced acute angle closure.
Topics: Adult; Antidepressive Agents, Tricyclic; Depressive Disorder, Major; Female; Glaucoma, Angle-Closure | 2015 |